Effect of gender on reporting of MMR adverse events in Saudi Arabia

Eastern Mediterranean Health Journal

Volumn 9, Issue 1-2, 2003, Pages 152-158

  Khalil, M K ^a   Al Mazrou, Y Y ^b   Al Ghamdi, Y S ^b   Tumsah, S ^b   Al Jeffri, M ^b   Meshkhas, A ^b  

^a King Fahd Specialist Hospital   (Saudi Arabia)

^b MINISTRY OF HEALTH   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ADOLESCENT; ARTICLE; ASEPTIC MENINGITIS; CHILD; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FEVER; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VIRUS; METHODOLOGY; MUMPS; MUMPS VIRUS; PAROTITIS; RUBELLA; RUBELLA VIRUS; SAUDI ARABIA; SEX DIFFERENCE; BODY MASS; HEALTH CARE QUALITY; HEALTH SURVEY; INFORMATION PROCESSING; METABOLIC CLEARANCE RATE; METABOLISM; ORGANIZATION AND MANAGEMENT; PREVENTIVE HEALTH SERVICE; RISK FACTOR; SAFETY; SEX RATIO; SEXUAL DEVELOPMENT; STANDARD;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; BODY MASS INDEX; CHILD; DATA COLLECTION; DRUG HYPERSENSITIVITY; FEMALE; FEVER; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; MALE; MEASLES-MUMPS-RUBELLA VACCINE; MENINGITIS, ASEPTIC; METABOLIC CLEARANCE RATE; PAROTITIS; POPULATION SURVEILLANCE; PROGRAM EVALUATION; RISK FACTORS; SAFETY; SAUDI ARABIA; SEX CHARACTERISTICS; SEX DISTRIBUTION;

EID: 16544371738     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Tran C et al. Gender differences in adverse drug reactions. Journal of clinical pharmacology, 1998, 38:1003-9.
2. Martin RM et al. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. British journal of clinical pharmacology, 1998, 46:505-11.
3. Fattinger K et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. British journal of clinical pharmacology, 2000, 49:158-67.
4. Knudsen KM et al. Child mortality following standard, medium or high titre measles immunization in West Africa. International journal of epidemiology, 1996, 25:665-73.
5. Aaby P et al. A comparison of vaccine efficacy and mortality during routine use of high-titre Edmonston-Zagreb and Schwarz standard measles vaccines in rural Senegal. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90:326-30.
6. Atabani S et al. Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines. Clinical and diagnostic laboratory immunology, 2000, 7:111-3.
7. 10 Edmonston-Zagreb measles vaccine. Saudi medical journal, 1993, 14:44-5.
8. Khalil M et al. Response to measles revaccination among toddlers in Saudi Arabia by the use of two different trivalent measles-mumps-rubella vaccines. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93:214-9.
9. Al-Mazrou YY et al. Measles immunization: early two-doses policy experience. Journal of tropical pediatrics, 1999, 45: 98-104.
10. Wharton M et al. Case definitions for public health surveillance. Morbidity and mortality weekly report. Recommendations and reports/Centers for Disease Control, 1990, 39:1-43.
11. Shohat T et al. Gender differences in the reactogenicity of measles-mumps-rubella vaccine. The Israel Medical Association journal 2000, 2:192-5.
12. Virtanen M et al. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics, 2000, 106:E62.
13. Martinez-Mir I et al. A prospective study of adverse drug reactions in hospitalized children. British journal of clinical pharmacology, 1999, 47:681-8.
14. Mark A, Carlsson RM, Granstrom M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine, 1999, 17:2067-72.
15. Beyer WE et al. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. European journal of clinical microbiology and infectious diseases, 1996, 15:65-70.
16. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs, 1995, 50: 222-39.
17. Vinge E. Man och kvinnor reagerar olika pa lakemedel. Hormonellt betingade farmakodynamiska skillnader foga studerade. [Men and women respond differently to drugs. Hormone-dependent pharmacodynamic differences are rarely studied.] Lakartidningen, 1998, 95:3177-82.
18. Mitchell LA. Sex differences in antibodyand cell-mediated immune response to rubella re-immunisation. Journal of medical microbiology, 1999, 48:1075-80.
19. Yalcin SS, Yurdakok K. Sex-specific differences in serum vitamin A values after measles immunization. The pediatric infectous disease journal, 1999, 18: 747-8.
20. Goodman E et al. Influences of gender and social class on adolescents' perceptions of health. Archives of pediatrics and adolescent medicine, 1997, 151: 99-904.
21. Carpenter JS et al. Do participants' reports of symptom prevalence or severity vary by interviewer gender? Nursing research 1999, 48:276-9.
22. D'Souza RM et al. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign. Communicable diseases intelligence, 2000, 24:27-33.
23. Kimura M et al. Adverse events associated with MMR vaccines in Japan. Acta paediatrica Japonica: Overseas edition, 1996, 38:205-11.
24. Virtanen M et al. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics, 2000, 106:E62.